Viva In Vitro Diagnostics ads

From Scientific Innovation to Scalable Solutions. A new milestone for #VIVAIVD! We are proud to announce our strategic partnership with ASKA Biotech, a specialised German #CDMO that will support the industrial development and manufacturing of #VIVAELISA®, targeting our first Research Use Only (#RUO) product in 2027, subject to successful development and product release. This collaboration marks another important step in our journey: turning differentiated science into reproducible and scalable solutions for precision immunology. At #VIVAIVD, we are developing a functional #NLRP3 biomarker platform that evaluates inflammasome pathway response capacity through ex vivo stimulation and ASC specks detection. Our progress builds on a strong scientific and business foundation, including multicentre collaborations with leading hospitals and research institutions, a protected IP portfolio, €2.5 million in #EICTransition funding and recognition by the European Commission's Innovation Radar. But scientific innovation also requires industrial execution. By combining VIVAIVD's proprietary technology with ASKA Biotech's specialised expertise in immunoassay development, biotechnology manufacturing and quality management, we are strengthening our European development roadmap. A special thank you to Anke Holzinger and Alexandra Rindermann, Siegmund Karasch, Susann Herrmann, Nane Börner and the entire ASKA team, as well as Dr. Verónica Cánovas, Pablo Gonzalez-Polanco, Mari Carmen Baños and everyone at Viva in Vitro Diagnostics contributing to this milestone. We also want to recognise the vision and commitment of our founders, the invaluable contribution of our scientific and clinical advisors, and the continued trust of our investors, business angels, family offices and institutional partners. Their support is essential to building a sustainable European biotechnology company. Science. Partnership. Execution. And, above all, People. Read the full announcement: https://lnkd.in/eukZMhyd #VivaInVitro #ASKABiotech #CDMO #Biotechnology #PrecisionMedicine #NLRP3 #VIVAELISA #Innovation

From scientific innovation to industrial execution. One of the biggest challenges in biotechnology is turning promising science into a reliable, scalable product. Our partnership with ASKA Biotech represents an important milestone in that journey for Viva In Vitro Diagnostics. Press Release: 👉 https://lnkd.in/eHY8p7mD For me, it is about more than selecting a #CDMO. It is about finding the right partner, building mutual trust and sharing a commitment to quality, execution and results. My sincere thanks to Anke Holzinger and the entire ASKA team for their professionalism and collaborative spirit, and to our VIVA team for their dedication throughout this process. There is still important work ahead, and we look forward to taking the next steps together. Great science needs great execution. And great partnerships make it possible.

VivaIVD en Diario EL PAÍS / Cinco Días. La lucha contra la #sepsis necesita más investigación, innovación y colaboración entre profesionales sanitarios, instituciones y empresas biotecnológicas. El diario Cinco Días dedica un amplio reportaje, firmado por la periodista Elena Sevillano, a los avances en inteligencia artificial, detección precoz y medicina personalizada para mejorar el abordaje de la sepsis. Lee el reportaje y las entrevistas completas aquí: https://lnkd.in/e_ng3BGF Un análisis que recoge la experiencia y visión de destacados especialistas y representantes del ecosistema sanitario y biotecnológico: Dr. Ricard Ferrer Roca, jefe del Servicio de Medicina Intensiva del Vall d'Hebron Barcelona Hospital Campus, que destaca la necesidad de reducir la variabilidad asistencial, avanzar en la estratificación del riesgo y personalizar los tratamientos. Dr. Carlos García Palenciano, jefe del Servicio de Anestesiología y Reanimación del Hospital Virgen de la Arrixaca, asesor clínico externo y fundador de Viva In Vitro Diagnostics, que subraya la importancia de invertir en investigación, anticipar las complicaciones y mejorar el pronóstico de los pacientes. Dr. Marcio Borges Sa, MD, PhD, presidente de la Fundación Código Sepsis, que comparte los resultados de la integración de inteligencia artificial y equipos clínicos especializados para mejorar la detección temprana y la atención hospitalaria. Ion Arocena, director general de AseBio - Asociación Española de Bioempresas, que pone en valor el papel de los biomarcadores funcionales, la biotecnología y la IA para avanzar hacia una medicina más personalizada. El reportaje también destaca el trabajo de Viva in Vitro Diagnostics en el desarrollo de biomarcadores funcionales relacionados con la activación del inflamasoma NLRP3, una línea de investigación orientada a mejorar la estratificación inmunológica de los pacientes. Como señala nuestro CEO, Toni Vilaplana Vivancos Vilaplana: "Gracias a Cinco Días por dar visibilidad a un desafío sanitario tan importante como la sepsis. Y, sobre todo, gracias a los profesionales, investigadores e instituciones que trabajan cada día para avanzar en su abordaje. Desde Viva queremos seguir construyendo juntos, conectando conocimiento científico, innovación y práctica clínica para transformar la investigación en soluciones que aporten valor real a los pacientes". En nuestro blog ampliamos sus contenidos con las declaraciones completas del Dr. Ricard Ferrer, el Dr. Carlos García-Palenciano e Ion Arocena, profundizando en los desafíos clínicos, científicos y tecnológicos de la sepsis. Artículo original en https://lnkd.in/euJEZAHK. #VivaInVitro #Sepsis #Biotecnología #Salud #Innovación #MedicinaPersonalizada #SepsisDiagnostics #LabMedicine #NLRP3

One of the greatest challenges in the fight against #Sepsis is bringing together research, scientific debate, knowledge sharing and collaboration. Seeing so many leading institutions, scientific organisations, biotech companies and pharmaceutical companies coming together at #ISICIP2026 reminds us of the scale of this challenge and, above all, how essential it is to work together. I'm proud that Viva In Vitro Diagnostics is once again sponsoring this important international meeting, organised by Fundación Código Sepsis. Special thanks to Dr Ricard Ferrer and Dr Ignacio Martin-Loeches, not only for their commitment to this symposium, but also for their invaluable contributions and connections as members of VIVA's Medical Advisory Board. We're going to Barcelona with two clear objectives: to learn from the best and to contribute our own knowledge and experience. We've made significant progress over the past year, and we're ready to share it. Looking forward to inspiring discussions, new connections and opportunities to move forward together. See you in Barcelona! https://www.isicip.com/ #PrecisionMedicine #Biotechnology #VivaInVitro

A year of progress, new partnerships and shared challenges. Looking forward to #ISICIP2026! I am delighted that Viva In Vitro Diagnostics will once again sponsor ISICIP, which celebrates its 30th anniversary on 29–30 October in Barcelona, bringing together leading international experts in sepsis, intensive care and infectious diseases. My sincere thanks to Fundación Código Sepsis, the International Sepsis Forum (ISF) and the entire Organising Committee for their continued commitment to advancing scientific knowledge and clinical practice. Special thanks to Dr Ricard Ferrer Roca and Dr Ignacio Martin-Loeches, with whom we also have the privilege of collaborating as members of VIVA's Medical Advisory Board. And, of course, to Isabel Montojo, whose dedication and coordination are essential to making this meeting possible. It has been an intense and exciting year since our last meeting. At #VIVAIVD, we have made significant progress in strengthening our clinical and scientific collaborations, including our work with Vall d'Hebron and VHIR on sepsis, and a new research collaboration with Vall d’Hebron Institute of Research (VHIR) - Vall d'Hebron Institut de Recerca and CEMCAT (Centre d'Esclerosi Múltiple de Catalunya) in multiple sclerosis, exploring the potential of functional #NLRP3 biomarkers to better understand therapeutic response. We have also expanded our collaboration network with INCLIVA Instituto de Investigación Sanitaria and Hospital Clínico Universitario de Valencia, alongside other hospitals and research institutions, as we continue advancing the development and clinical validation of our technology. All these initiatives share a common vision: turning functional immune information into meaningful insights for precision medicine, with sepsis as our first clinical application and opportunities to explore other inflammatory and immune-mediated diseases. I am also particularly proud that VIVA represents European biomedical innovation, supported by €2.5 million in funding from the EIC - European Innovation Council (EIC) Transition programme, under the European Commission 's Horizon Europe framework. This support is helping us bridge the gap between scientific discovery and future clinical applications. But innovation is never a journey undertaken alone. ISICIP is also an opportunity to listen, exchange ideas and explore new collaborations. I look forward to meeting clinicians, researchers, hospitals, biotech and pharmaceutical companies, and other stakeholders during the congress to discuss how we can work together on the challenges we share. If you are attending ISICIP 2026, I would be delighted to connect. See you in Barcelona! https://www.isicip.com/ #ISICIP2026 #Sepsis #PrecisionMedicine #Biomarkers #Immunology #Biotechnology #Innovation #VivaInVitro #EICTransition

Science, innovation and international collaboration come together once again at #ISICIP2026. Viva in Vitro Diagnostics is proud to support this international symposium as a sponsor for another year. On 29–30 October, Barcelona will host the International Symposium on Infections in the Critically Ill Patient, promoted by Fundación Código Sepsis in collaboration with the International Sepsis Forum (#ISF). What's on the agenda? 🗣️ Sepsis and precision medicine: immune phenotypes and patient stratification. 🗣️ Next-generation diagnostics: functional biomarkers and multi-omics. 🗣️ AI and the digital ICU: turning data into better clinical decisions. Immunomodulation and new therapeutic strategies. Severe respiratory infections and antimicrobial resistance. The programme features leading international experts, including Chris Seymour, Manu Shankar-Hari FRSE FMedSci, Tom van der Poll, Paula Ramirez, Mervyn Singer, Kathy Rowan, Fernando Ramasco Rueda, Derek Angus, Evangelous Giamarellos-Bourboulis, Otavio Ranzani, Silvia De Rosa, Jose Garnacho, Antoni Torres and Antonio Artigas. Special recognition to Dr Ricard Ferrer Roca and Dr Ignacio Martin-Loeches, members of the Organising Committee and valued members of VIVA's Medical Advisory Board. At VIVA, a biotech company funded by the European Innovation Council and SMEs Executive Agency (EISMEA) (EIC - European Innovation Council) of the European Commission, we are developing a functional biomarker platform for immune stratification, with sepsis as our first clinical application. Our team will be in Barcelona: Toni Vilaplana Vivancos, Verónica Cánovas and Pablo Gonzalez-Polanco, Mari Carmen Baños, ready to exchange ideas and explore new collaborations. We also recognise the support of Federación Panamericana e Ibérica de Medicina Crítica y Terapia Intensiva - FEPIMCTI, Global Sepsis Alliance, Micellium Fundación, Sociedad Española de Medicina Intensiva, Crítica y Unidades Coronarias (SEMICYUC), Sociedad Española de Neumología y Cirugía Torácica (SEPAR), Sociedad Española de Quimioterapia, Societat Catalana de Medicina i Infermeria Intensiva i Critica and Sociedade Galega de Medicina Intensiva e Unidades Coronarias. Our thanks to Fundación Código Sepsis, the Organising and Scientific Committees, and especially Isabel Montojo for her outstanding coordination. See you in Barcelona! Discover the full programme: https://www.isicip.com/ #ISICIP2026 #Sepsis #PrecisionMedicine #Biomarkers #Biotechnology #Innovation #VivaInVitro